DEFA14A: NanoVibronix Corrects Preferred Stock Disclosure for Special Stockholder Meeting

NanoVibronix, Inc. filed a supplement to its definitive proxy statement to correct an inadvertent error regarding the number of outstanding Series G and Series X Preferred Stock shares ahead of its Special Meeting on July 11, 2025.

Summary

• NanoVibronix, Inc. filed a supplement to its definitive proxy statement on Schedule 14A.
• The supplement corrects an inadvertent error on page 3 of the original proxy statement regarding the number of preferred stock shares outstanding as of the Record Date.
• The original proxy statement incorrectly stated that there were no shares of any series of preferred stock outstanding.
• The corrected disclosure confirms that 320,348 shares of Series G Preferred Stock and 57,720 shares of Series X Preferred Stock were issued and outstanding as of the Record Date.
• This correction solely affects the disclosure related to these preferred stock shares outstanding as of the Record Date.
• Holders of Common Stock (2,282,746 shares), Series G Preferred Stock (320,348 shares), and Series X Preferred Stock (57,720 shares) as of the Record Date are entitled to vote at the Special Meeting.
• Stockholders who have already submitted their proxy do not need to take further action unless they wish to change their vote.

Sentiment

Score: 5

Explanation: The document is a factual correction of a disclosure error, not indicating positive or negative operational or financial performance. It reflects standard regulatory compliance.

Risks

• The document addresses a prior disclosure inaccuracy regarding the number of outstanding preferred stock shares, which could have led to confusion regarding voting entitlements if not corrected.

Future Outlook

The document does not provide any forward-looking statements or guidance beyond the scheduled Special Meeting date.

Industry Context

This filing is a standard regulatory disclosure correction, not indicative of broader industry trends or competitive dynamics. It reflects a company's adherence to SEC disclosure requirements.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides accurate information regarding the number of outstanding preferred shares and their voting entitlements for the upcoming Special Meeting, ensuring transparency and proper exercise of voting rights.

Next Steps

• The Special Meeting of Stockholders will proceed as scheduled on July 11, 2025.

Key Dates

Keywords

NanoVibronix, Proxy Statement, Special Meeting, Preferred Stock, Common Stock, SEC Filing, Corporate Governance, Shareholder Vote, DEFA14A, Disclosure Correction